Assembly Biosciences Inc (ASMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has a cash flow conversion efficiency ratio of -0.111x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.10 Million) by net assets ($198.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Assembly Biosciences Inc's balance sheet to measure how much of total assets are equity-financed.
Assembly Biosciences Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ASMB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Assembly Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assembly Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sweco AB (publ)
ST:SWEC-A
|
-0.005x |
|
Napatech A/S
OL:NAPA
|
-0.214x |
|
Husqvarna AB (publ)
ST:HUSQ-A
|
-0.066x |
|
Ways Electron Co Ltd
SHG:605218
|
0.005x |
|
Inventronics Hangzhou Inc
SHE:300582
|
0.014x |
|
Bank Tabungan Pensiunan Nasional Syariah PT
JK:BTPS
|
0.024x |
|
First Tractor Company Limited
F:FTP
|
0.097x |
|
Sports Toto Berhad
KLSE:1562
|
0.149x |
Annual Cash Flow Conversion Efficiency for Assembly Biosciences Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see ASMB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $206.75 Million | $-41.09 Million | -0.199x | +87.03% |
| 2024-12-31 | $33.36 Million | $-51.12 Million | -1.532x | -376.89% |
| 2023-12-31 | $41.10 Million | $22.74 Million | 0.553x | +154.16% |
| 2022-12-31 | $82.66 Million | $-84.46 Million | -1.022x | -84.81% |
| 2021-12-31 | $168.93 Million | $-93.40 Million | -0.553x | -111.27% |
| 2020-12-31 | $240.58 Million | $-62.96 Million | -0.262x | +14.95% |
| 2019-12-31 | $273.22 Million | $-84.07 Million | -0.308x | +0.22% |
| 2018-12-31 | $210.65 Million | $-64.96 Million | -0.308x | -1975.30% |
| 2017-12-31 | $113.12 Million | $1.86 Million | 0.016x | +103.77% |
| 2016-12-31 | $79.88 Million | $-34.88 Million | -0.437x | -177.33% |
| 2015-12-31 | $118.74 Million | $-18.70 Million | -0.157x | +38.41% |
| 2014-12-31 | $58.57 Million | $-14.97 Million | -0.256x | +64.81% |
| 2013-12-31 | $24.49 Million | $-17.80 Million | -0.727x | +39.48% |
| 2012-12-31 | $17.81 Million | $-21.38 Million | -1.200x | -65.36% |
| 2011-12-31 | $34.53 Million | $-25.07 Million | -0.726x | -61.86% |
| 2010-12-31 | $11.63 Million | $-5.21 Million | -0.449x | -272.03% |
| 2009-12-31 | $-13.36 Million | $-3.48 Million | 0.261x | -40.55% |
| 2008-12-31 | $-9.46 Million | $-4.15 Million | 0.439x | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more